Skip to content

US · ADPT · BIOTECHNOLOGY

Adaptive Biotechnologies Corporation (ADPT) intrinsic value and stock valuation

$27.93as of 2026-11-21 · Mkt cap 3.99B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Adaptive Biotechnologies Corporation DCF and intrinsic value

InvestorsCraft values ADPT with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ADPT’s statements →

Adaptive Biotechnologies Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Seattle, WA 98109 adaptivebiotech.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$277M+23% 5y CAGRd
20172025
Net income
-$-59.5M
20172025
Free cash flow
-$-48.95M
20172025
Total equity
$225M-21.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$277M$179M$170.3M$185.3M$154.3M
Operating income-$-57.12M-$-162.55M-$-227.03M-$-200.19M-$-208.97M
Net income-$-59.5M-$-159.49M-$-225.25M-$-200.19M-$-207.28M
EPSd-$-392.17K-$-1.08M-$-1.56M-$-1.4M-$-1.48M
Operating cash flow-$-45.99M-$-95.21M-$-156.32M-$-183.94M-$-192.73M
Capital expenditure-$-2.96M-$-3.66M-$-10.7M-$-16.35M-$-61.75M
Free cash flow-$-48.95M-$-98.88M-$-167.02M-$-200.29M-$-254.47M
Total assets$512.7M$539.4M$661.1M$856.6M$923.3M
Total debt$280.6M$89.4M$98.8M$108M$111.7M
Net debt$210.1M$41.5M$33.7M$18M-$-27.32M
Total equity$225M$202.5M$308.3M$464.1M$604.1M
Cash and short-term investments$227M$222.3M$346.4M$498.2M$353.1M
Income statement
20252024202320222021
Revenue$277M$179M$170.3M$185.3M$154.3M
Cost of revenue$71.4M$72.1M$75.6M$57.9M$49.3M
Gross profit$205.6M$106.9M$94.7M$127.4M$105M
Research and development expenses$93.8M$103M$122.1M$141.8M$142.3M
Selling, general and administrative expenses$167.3M$157.6M$172.5M$184.1M$170M
Other expenses$1.7M$8.91M$27.1M$1.7M$1.7M
Operating expenses$262.7M$269.4M$321.8M$327.6M$314M
Cost and expenses$334.1M$341.5M$397.3M$385.5M$363.3M
Interest income$9.44M$14.5M$15.5M$4.06M$1.67M
Interest expense$11.8M$11.6M$13.8M$4.24M$0.00
Depreciation and amortization$17.8M$19.3M$22.2M$20.9M$14M
Ebitda-$-29.85M-$-128.76M-$-189.27M-$-175.21M-$-193.34M
Operating income-$-57.12M-$-162.55M-$-227.03M-$-200.19M-$-208.97M
Total other income/expenses, net-$-2.33M$2.95M$1.73M-$-180K$1.67M
Income before tax-$-59.46M-$-159.59M-$-225.3M-$-200.37M-$-207.3M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-59.5M-$-159.49M-$-225.25M-$-200.19M-$-207.28M
Weighted average shares outstanding$151.7M$147.1M$144.4M$142.5M$140.4M
Weighted average diluted shares outstanding$151.7M$147.1M$144.4M$142.5M$140.4M
Balance sheet
20252024202320222021
Cash and short-term investments$227M$222.3M$346.4M$498.2M$353.1M
Net receivables$50.4M$41.7M$38M$40.1M$17.4M
Inventory$9.82M$8.44M$14.5M$14.5M$19.3M
Total current assets$300.2M$283.8M$410.2M$562.2M$402.8M
Property, plant and equipment, net$74.7M$94.4M$120.3M$164.2M$172.9M
Goodwill and intangible assets$120.7M$122.4M$124.1M$125.8M$127.5M
Long-term investments$15.9M$33.7M$0.00$0.00$217.2M
Total non-current assets$212.6M$255.6M$251M$294.5M$520.6M
Total assets$512.7M$539.4M$661.1M$856.6M$923.3M
Accounts payable$6.47M$7.26M$7.72M$8.08M$3.31M
Short-term debt$13.6M$10.2M$9.38M$9.23M$5.05M
Deferred revenue$45.2M$55.7M$48.6M$64.1M$80.5M
Total current liabilities$89.9M$98.1M$88M$109.8M$113.8M
Long-term debt$267M$79.2M$89.4M$98.8M$106.7M
Deferred revenue, non-current$1.01M$27.3M$44.8M$58.6M$98.8M
Total non-current liabilities$197.8M$238.8M$264.8M$282.7M$205.4M
Capital lease obligations$70.2M$89.4M$98.8M$108M$111.7M
Total liabilities$287.7M$336.9M$352.9M$392.5M$319.2M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.36B-$-1.3B-$-1.14B-$-919.08M-$-718.89M
Accumulated other comprehensive income (loss)$250K$170K$210K-$-4.12M-$-1.14M
Total equity$225M$202.5M$308.3M$464.1M$604.1M
Total investments$172.4M$208M$281.3M$408.2M$431.1M
Total debt$280.6M$89.4M$98.8M$108M$111.7M
Net debt$210.1M$41.5M$33.7M$18M-$-27.32M
Cash flow statement
20252024202320222021
Net income-$-59.5M-$-159.59M-$-225.25M-$-200.19M-$-207.28M
Depreciation and amortization$17.8M$19.3M$22.2M$28.2M$21M
Stock-based compensation$51.5M$53.6M$0.00$0.00$0.00
Change in working capital-$-57.77M-$-17.45M-$-46.18M-$-71.55M-$-56.82M
Accounts receivable-$-8.65M-$-3.74M$2.03M-$-22.65M-$-7.36M
Inventory-$-1M$1.94M-$-2.84M$820K-$-5.2M
Accounts payable$670K$670K-$-5.41M$7.11M$3.94M
Net cash provided by operating activities-$-45.99M-$-95.21M-$-156.32M-$-183.94M-$-192.73M
Investments in property, plant and equipment-$-2.96M-$-3.66M-$-10.7M-$-16.35M-$-61.75M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$38M$77.8M$129.7M$2.9M$181.2M
Common stock issued$30.4M$240K$2.25M$7.89M$26.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30.4M$240K$2.25M$132.3M$27.2M
Net change in cash$22.4M-$-17.18M-$-24.97M-$-49.03M$15.6M
Cash at end of period$73.2M$50.8M$65.1M$90M$139.1M
Operating cash flow-$-45.99M-$-95.21M-$-156.32M-$-183.94M-$-192.73M
Capital expenditure-$-2.96M-$-3.66M-$-10.7M-$-16.35M-$-61.75M
Free cash flow-$-48.95M-$-98.88M-$-167.02M-$-200.29M-$-254.47M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Adaptive Biotechnologies Corporation

        Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

        CEO
        Chad Robins
        Employees
        624
        Beta
        2.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Adaptive Biotechnologies Corporation (ADPT)?

        Adaptive Biotechnologies Corporation (ADPT) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ADPT undervalued?

        ADPT trades at a price of $27.93 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.